XML 130 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Financial Instruments
 6 Months Ended
Jun. 30, 2024
Investments, All Other Investments [Abstract]  
Financial Instruments

5. Financial Instruments

 

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

 

The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of:

 

   June 30, 2024 
   cost   Unrealized
Gain/(Loss)		   Fair
Value		   Cash and
Cash
Equivalents		   Marketable
Securities		 
Cash  $10,649,000   $-   $10,649,000   $10,649,000   $- 
Level 1                         
Money Market Funds   70,000    -    70,000    70,000    - 
Marketable Securities   26,984,000    (17,426,000)  $9,558,000    -    9,558,000 
Total  $37,703,000   $(17,426,000)  $20,277,000   $10,719,000   $9,558,000 

 

   December 31, 2023 
  

Adjusted

Cost

  

Unrealized

Gain/(Loss)

  

Fair

Value

  

Cash and

Cash

Equivalents

  

 

Marketable

Securities

 
Cash  $6,545,000   $-   $6,545,000   $6,545,000   $- 
Level 1                         
Money Market Funds  $70,000    -   $70,000    70,000    - 
Marketable Securities  $27,304,000    (17,325,000)  $9,979,000    -    9,979,000 
Total  $33,919,000   $(17,325,000)  $16,594,000   $6,615,000   $9,979,000 

 

The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.